More importantly, in the MB49 tumor‐bearing immunocompetent C57BL/6J mouse model (Figure S13A, Supporting Information), the combination of EGCG with anti‐PD‐1 antibody was more efficient in inhibiting tumor growth and increasing the infiltration of CD8+ T cells into tumor than either EGCG or anti‐PD‐1 antibody alone (Figure 8E–H; Figure S13B, Supporting Information). Here, CD8A is linked to neoplasm.